EAM Investors’s Relmada Therapeutics RLMD Stock Holding History

EAM Investors’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$911K	Sell	130,935 -31,617	-19%	-$150K	0.11%	217
2025 Q4	$785K	Buy	+162,552	New	+$545K	0.09%	231

Other funds holding RLMD

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

SSC

Spruce Street Capital New York $416M AUM

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM Investors's RLMD Position: Q1 2026 in Review

EAM Investors reduced its Relmada Therapeutics (RLMD) stake by 19% in Q1 2026, selling an estimated $150K and leaving 130,935 shares worth $911K. The position accounts for 0.11% of the portfolio, ranked #217.

EAM Investors first reported a position in RLMD in Q4 2025 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

EAM Investors held 130,935 shares of Relmada Therapeutics worth $911K as of Q1 2026.
EAM Investors sold 31,617 Relmada Therapeutics shares in Q1 2026, an estimated $150K.
Relmada Therapeutics made up 0.11% of EAM Investors's portfolio in Q1 2026, its #217 holding.
EAM Investors first reported a position in Relmada Therapeutics in Q4 2025 and has held it in 2 quarters since.
103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.